Given dopamine’s inhibitory effect on PRL release, medical treatments based on dopamine agonists (e.g., bromocriptine or cabergoline) (Krysiak & Okopień 2019) are currently the first-line of treatment for patients suffering from HPRL. Here, PRL is linked to familial hyperprolactinemia.